objeCtives: To evaluate the degree to which the officially pre-determined cost and average length of stay (ALoS) per selected KEN-DRG reflect actual resource use and to investigate other factors (e. g. size, type and location of hospital) correlated with charges and ALoS. Methods: Data were from the Health Regions data base and included discharges, ALoS, and charges in NHS Hospitals for the selected KEN-DRGs. Predetermined ALoS and cost per KEN-DRG were derived from Gazette 946/27/03/2012. Continuous variables did not follow normal distribution, so non parametric methods (Spearman's correlation coefficient, Kruskal-Wallis test and Mann-Whitney test) were used. A two sided p-value ≤ 0.05 was considered statistically significant. Results: Higher length of stay compared with the officially pre-determined was found for Chronic Obstructive Pulmonary Disease (COPD) with complications (10.8 vs 9 days), Bronchitis & Asthma with complications (5.8 vs 4 days), Bronchitis & Asthma without complications (2.7 vs 2 days) and Breast Cancer with complications (7.9 vs 5 days). Consequently, officially pre-determined cost for Breast Cancer with complications (€ 965), Bronchitis & Asthma with complications (€ 792) and COPD with complications (€ 1,446) represents less than 90% of total hospital charges (total actual average charge: € 1,186; € 929; € 1,634 respectively). However, for the rest of the DRGs, under study, there were none or limited additional hospital charges. For all KEN-DRGs, size and population density was positively correlated with total charges (r s = 0.12, p= 0.018; median for Athens = 863 & semi-urban= 752 p= 0.09 respectively). Moreover, for Bronchitis & Asthma with and without complications, population density was found to be positively correlated with ALoS (median for urban areas= 5.1 and semi-urban= 4.7; p= 0.09 and median for urban areas= 3 and semi-urban= 2.5; p= 0.03 respectively). ConClusions: The introduction of KEN-DRGs was a useful first step to modernize the hospital reimbursement system. However, further revisions are required in order for KEN-DRGs to become more useful. objeCtives: Asthma is under-diagnosed and under-treated in elderly, and utilization of asthma medications in this population is not well characterized. This study describes utilization patterns of asthma medications in newly diagnosed ≥ 50 patients. Methods: Medicare enrollees are followed for 12 months after first asthma diagnosis between Q1 2004-Q3 2012 (ICD-9-CM code: 493*). Treatment pattern analysis was applied to initiators of asthma medications. Patients with > 1 prescription of second-line therapy following exposure to first-line therapy are considered therapy switchers or augmenters. Patients with history of chronic obstructive pulmonary disease are excluded (ICD-9-CM codes: 490, 491*, 492*, 494*, 495* & 496). Results: Among 126,176 elderlies with asthma, 24,021 initiated asthma therapy within 12 months of asthma diagnosis (70% women, median age 70 years). 319 (1.3%) continued therapy with one drug class (first-line therapy); 13,940 (58%) discontinued first-line therapy; 3,469 (14.4%) switched to another drug class (second-line therapy); and 6,293 (26.2%) added second-line therapy (augmented). About 34% of patients initiated therapy with inhaled short-acting beta-agonists (SABA); majority of them either discontinued SABA or added a controller medication. 19% of elderly patients started with oral corticosteroids after asthma diagnosis, 77% discontinued them and 12% switched to another asthma controller. Among controller medications, inhaled corticosteroids (ICS) /long-acting beta-agonists (LABA) combination therapy, ICS monotherapy, and leukotriene antagonists respectively accounted for 19%, 12%, and 11% of treatment initiators. The majority of these antiare directly and indirectly linked with HRQoL of TB patients. Methods: A prospective cross-sectional study was conducted at a tertiary care hospital in a province of Pakistan, the Punjab. Data was collected by using WHOQOL-BREF questionnaire (Urdu version, pretested for reliability and validity) by means of face-to-face interviews and where possible by gender-based focus group sessions. In addition, facilitators also used few open-ended questions in order to get patients' demographic and socioeconomic data. Participants were also asked to share their personal experiences of being diagnosed and treated with TB and what impact it had on their life style. All obtained data were analyzed using descriptive and inferential statistics. Results: The overall Cronbach's alpha coefficient of the revalidated WHOQOL-BREF questionnaire was 0.785. The confirmatory factor analysis also provided an acceptable fit to a four-factor model in the studied sample. The scores for negative feelings, blue mood, depression, living place, personal relationships and sex life were significantly different in the psychological health and social relations domains. Age, gender and physical exercise were also significantly associated with the HRQoL of the patients. ConClusions: The WHOQOL-BREF was reliable and valid in the assessment of the HRQoL of TB patients in Pakistan. Despite the ability to cure TB, there was a significant impact on HRQoL of the TB patients. Till today, much attention is spent on curative and preventative mechanisms whereas the impact of TB on HRQoL is often neglected. objeCtives: To assess published data on perennial allergic rhinitis/house dust mite allergic (PAR) patients and seasonal allergic rhinitis/grass pollen allergic (SAR) patients in order to establish the burden of allergic rhinitis (AR) and allergic asthma from both a quality of life (QoL) and cost perspective. Methods: A systematic literature review was conducted using Medline and Embase in eight pre-specified countries for the time period of January 2000 to January 2014. Search terms were related to QoL and/or cost. A total of 2963 abstracts and titles were identified. 50 abstracts met predefined criteria and provided data for calculations and collation. Results: Based on the RQLQ, the overall QoL of PAR patients was significantly worse than that of SAR patients (2.73 ± 0.12 cf. 2.04 ± 0.18, p≤ 0.001). In general, practical problems (mean: 3.80 ± SE: 0.08) and activities (mean: 3.70 ± SE: 0.11) were the most affected domains. Measured by the physical component score from the SF-36 questionnaire, the overall QoL of PAR patients was worse (p= 0.002) than that of SAR patients (49.06 ± 1.26 cf. 64.19 ± 7.89). For both PAR and SAR patients, domains measured by the SF-36 showed that vitality (mean: 59.95 ± SE: 3.24) was the most affected domain. Based on RQLQ, allergy immunotherapy improves eye symptoms, nasal symptoms, activities and practical problems the most in grass allergic patients. Direct comparison of total direct and indirect costs was complicated by differences in individual costs assessed among studies, however, the primary burden of costs is indirect and caused by high absenteeism and presenteeism. ConClusions: The QoL and economic burden of AR was substantial in the countries included in this review. However, limitations regarding the number of studies per country, heterogeneity between studies, and the lack of presented data have restricted the conclusions that could be drawn. objeCtives: To determine the Quality of Life (QoL) of bronchial asthma patients in a tertiary care teaching hospital at baseline and at follow up. Methods: The study was conducted for a period of 6 months among 100 bronchial asthma patients, with and without co-morbidities, admitted to the pulmonary and medicine wards in the university hospital after obtaining the ethical clearance. The quality of life was assessed using Asthma Quality Of life Questionnaire (AQLQ). Patients were followed up after 4weeks from the date of discharge. Statistical analysis was performed using SPSS version 20. Results: The mean age of the study population was 53.30±14.59 having 61% of the patients as females. Data was analyzed by Wilcoxon signed rank test. The total score of Qol at follow up (5.94 ±0.76) showed an improvement with a P value < 0.0001 (wilcoxon signed rank t test) when compared with baseline (3.92 ± 1.04). A significant improvement in symptoms was seen at follow up (6.05 ± 0.82) from baseline (3.93 ± 1.14). The activity limitation improved with a P value < 0.0001 (Wilcoxon signed rank t test) from baseline (4.00 ± 1.08) to follow up (5.92 ± 0.83). At follow up (5.97 ± 0.82) the emotional function showed an enhancement on comparing with baseline (3.92 ± 1.14). The environmental stimuli showed no significant changes at baseline (3.66 ± 1.29) and follow up (3.84 ± 1.34). ConClusions: The results of the study suggests that clinical pharmacists have a major role in improving patient knowledge and thereby significantly improve the quality of life of the patient. objeCtives: Patient satisfaction with asthma treatment is associated with better adherence and achievement of treatment goals. While medication changes are sometimes instigated for clinical or financial reasons, changes without patients' knowledge or involvement ('non-consented switch' [NCS]) can impact symptom control and patient-health care provider (HCP) relationships. This study explored experiences of patients who had a NCS and subsequently requested and received a second switch (SS). Methods: Interviews were conducted with 13 UK adult asthma
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